Fungal Infections

FDA Fast Tracks New Oral Antifungal to Treat Valley Fever

By July 13, 2017

VT-1598, an oral fungal CYP51 inhibitor, has shown high potency against pathogens such as molds, yeasts, and multi-drug resistant fungal pathogens (eg, Candida auris).

Addition of Antifungal to Cancer Tx Leads to Nephrotic Syndrome

July 07, 2017

Case report of patient with relapsed Hodgkin's lymphoma treated with everolimus for five years

Therapies Compared for Treating Deadly Fungal Infection in HIV Patients

June 15, 2017

Compared with itraconazole, amphotericin treatment correlated with significantly faster clinical resolution and fungal clearance and with significantly lower rates of relapse and immune reconstitution inflammatory syndrome.

Plant Found to Harbor Drug-Resistant Fungal Pathogen

By May 18, 2017

Results showed that 5 of the 6 bulb packages tested positive for triazole-resistant A. fumigatus.

Meningitis, Encephalitis Caused by Viruses Mostly in the U.S.

By April 20, 2017

Enterovirus was found to be the most common etiology (50.9%), followed by unknown (18.7%), bacterial meningitis (13.9%), herpes simplex virus (8.3%), non-infectious (3.4%), fungal (2.7%), arboviruses (1.1%), and other viruses (0.8%).

Infant's Tongue Lesion Mimics Neoplastic Growth

April 10, 2017

"This case reinforces the role of tissue culture when histology fails to demonstrate a diagnosis and emphasizes the need for efficient communication between the pediatrician, otolaryngologist, and pathologist for timely excision," the authors write.

Thrombotic Microangiopathy Cases Prompt Update to Antifungal Drug Labeling

By January 25, 2017

The labeling for Lamisil (terbinafine hydrochloride) Tablets and Oral Granules has been updated to include a new warning regarding the risk of thrombotic microangiopathy.

Dr. Reddy's Launches Generic Topical Antifungal Cream

By December 06, 2016

Dr. Reddy's Laboratories has announced the launch of Nystatin and Triamcinolone Acetonide Cream, the generic equivalent of Taro Pharmaceutical's Nystatin and Triamcinolone Acetonide Cream, USP 100,000/g 0.1%.

Naftin Labeling Updated with Pediatric Usage Information

By November 29, 2016

The Food and Drug Administration (FDA) has approved new labeling for Naftin (naftifine HCl cream 2%; Merz Pharmaceuticals) adding additional information regarding use in the pediatric population.

CDC Reports on Emerging Pathogenic Fungus in the U.S.

November 04, 2016

The CDC announced an alert in June 2016 requesting all clinicians, laboratory workers, infection control practitioners, and public health authorities report C. auris cases.

Posaconazole Prophylaxis Safe in Routine Clinical Use for Hematological Malignancies

By October 28, 2016

Both the tablet and intravenous (IV) formulations of posaconazole appeared to be safe and effective for primary prophylaxis against invasive fungal infections in patients with hematologic malignancies, according to results of a retrospective cohort study presented at IDWeek 2016.

Novel Treatment for Recurrent Vulvovaginal Candidiasis Gets Fast Track Status

By October 13, 2016

Viamet has announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designation to VT-1161, a novel treatment for recurrant vulvovaginal candidiasis (RVVC).

Does Empirical Micafungin Improve Survival in Critically Ill Patients?

October 07, 2016

No increase in invasive fungal infection-free survival for ICU-acquired sepsis, Candida colonization

Potent Oral Antifungal Granted QIDP Status for Valley Fever

By September 15, 2016

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis, or Valley Fever.

Antifungal-Chemotherapy Drug Interaction Update

By September 13, 2016

The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.

Inhaled Antifungal Granted Orphan Drug Status for Cystic Fibrosis

By August 22, 2016

The Food & Drug Administration has granted Orphan Drug designation to PUR1900 (Pulmatrix) for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF).

New Guidelines on Invasive Aspergillosis Diagnosis, Treatment Released

By July 05, 2016

The Infectious Diseases Society of America (IDSA) announced the release of updated guidelines on the diagnosi sand treatment of major forms of aspergillosis. The full guidelines are published in Clinical Infectious Diseases.

Drug Interaction Leads to Subtherapeutic Treatment for Patient with Fungal Brain Abscess

By June 22, 2016

Using the Drug Interaction Probability Scale this interaction scored a 7 out of 10 indicating probable interaction.

Lupin Approved for Generic Vfend Tablets, Oral Suspension

By June 13, 2016

Lupin announced that the Food and Drug Administration (FDA) has granted final approval for Voriconazole Tablets and Oral Suspension, the generic version of Pfizer's Vfend.

FDA Grants Antifungal Orphan Drug Status for Valley Fever

By May 25, 2016

The Food and Drug Administration (FDA) has granted Orphan Drug designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis or Valley Fever, a common lung infection in the southwestern US.

Unapproved Use of Antifungal Linked to Patient Death

By May 19, 2016

This medication should not be used to treat skin and nail fungal infections.

Serious Cardiac Arrhythmia Linked to Antifungal in AFib Patient with Esophageal Candidiasis

By May 18, 2016

Clinicians should be aware of this possible adverse event and monitor patients receiving concomitant drugs that may prolong the QT interval.

FDA Issues Advisory for Antifungal After Reports of Miscarriage Risk

By April 26, 2016

The Food and Drug Administration (FDA) is advising caution when prescribing oral fluconazole (Diflucan) in pregnancy after evaluating data from a Danish study that indicated a possible increased risk of miscarriage when used to treat yeast infections.

Laser Plus Topical Antifungal Effective for Onychomycosis

April 22, 2016

Fractional carbon dioxide laser therapy combined with topical antifungal is effective in the treatment of onychomycosis.

RECALL: Metronidazole Identified in Fluconazole Injection

By March 07, 2016

Sagent announced a voluntary recall of 1 lot of Fluconazole Injection, USP, 200mg/100mL due to the discovery of an out of specification impurity result.

Contaminated Suspending Agents Used for Compounding Recalled

By February 11, 2016

Fagron, Inc. is voluntarily recalling certain lots of SyrSpend SF and SyrSpend SF Grape suspending agents used in various oral liquid compounded products due to the presence of Candida galli, a type of yeast.

Orphan Drug Designation Granted to Novel Echinocandin

By February 10, 2016

The Food and Drug Administration (FDA) has granted Orphan Drug designation to CD101 IV (Cidara Therapeutics) for the treatment of candidemia and invasive candidiasis.

Dosing Errors with Antifungal Agent Prompt FDA to Issue Warning

By January 04, 2016

The Food and Drug Administration (FDA) is cautioning that dosing errors for Noxafil (posaconazole) delayed-release tablets and oral suspension have resulted due to differences in dosing regimens between the two formulations.

Empirical Treatment More Cost-Effective for Onychomycosis

December 28, 2015

For onychomycosis, empirical therapy with terbinafine more cost-effective than confirmatory testing

Positive Topline Data for Antifungal Tx Published

By December 10, 2015

Astellas announced that topline data from the pivotal Phase 3 trial, SECURE, which evaluated Cresemba (isavuconazonium sulfate) in adult patients with invasive aspergillosis were published in The Lancet.